Form 4: Vericel Corp Executive Jonathan Siegal Reports Stock Transactions

Principal Accounting Officer Jonathan Siegal of Vericel Corp reports acquisition and disposal of common stock and restricted stock units.

Summary

• On February 24, 2025, Jonathan Siegal, Principal Accounting Officer of Vericel Corp, acquired 1,875 shares of common stock upon vesting of Restricted Stock Units (RSUs) at a price of $0.
• On the same day, 738 shares were withheld by the issuer to cover tax obligations related to the RSU vesting at $52.33 per share.
• On February 25, 2025, Siegal sold 1,137 shares of common stock at $52.07 per share under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Siegal directly owns 1,206 shares of common stock.
• Siegal also holds 5,625 Restricted Stock Units (RSUs) that will vest in annual installments on February 22, 2026, February 22, 2027, and February 22, 2028.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive, with no inherent positive or negative sentiment. It reflects routine compensation and trading activities.

Future Outlook

The reporting person holds additional RSUs that will vest in annual installments on February 22, 2026, February 22, 2027, and February 22, 2028.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the trading activities of company executives. It is common for executives to have pre-arranged trading plans, such as Rule 10b5-1 plans, to manage their stock transactions and avoid accusations of insider trading.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, ensuring compliance with SEC regulations.
• The use of Rule 10b5-1 trading plans is a common strategy among executives to automate stock sales and avoid potential insider trading concerns, similar to practices seen at companies like Amgen, Biogen, and Gilead Sciences.
• The vesting schedule of the RSUs is typical for executive compensation packages, aligning with industry norms for incentivizing long-term performance, comparable to vesting schedules at companies like Vertex Pharmaceuticals and Regeneron.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares sold.
• The tax withholding impacts the company's cash flow, although the amount is likely immaterial.

Key Dates